Investigation the effects of Arctium Lappa root powder on some markers of oxidative stress and inflammation in women with polycystic ovary syndrome: a randomized double blind clinical trial study
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
بررسی تاثیر پودر ریشه گیاه بابا آدم بر سطح سرمی برخی متغییر های بیوشیمیایی در زنان مبتلا به سندرم تخمدان پلی کیستیک
بررسی تاثیر پودر ریشه گیاه بابا آدم بر سطح سرمی برخی متغیرهای بیوشیمیایی در زنان مبتلا به سندرم تخمدان پلی کیستیک
بررسی تاثیر پودر ریشه گیاه بابا آدم بر سطح سرمی برخی متغییر هایمتغیرهای بیوشیمیایی در زنان مبتلا به سندرم تخمدان پلی کیستیک
The purpose of the study and how to do it will be explained to patients and written consent will be obtained from them to participate in the study in Taleghani hospital, Arak. Blood samples are taken from patients at the beginning of the study (Sampling is done in the clinic) and factors such as blood fat and etc. are measured in the blood (measurement is done in the university laboratory).Then, the herbal medicine will be used in the participants for 12 weeks, and after this period, blood samples will be taken again and the factors will be measured again in order to evaluate the effect of the medicine. Patients will not be aware of the type of drug and the statistician will not be aware of the type of groups.
The purpose of the study and how to do it will be explained to patients and written consent will be obtained from them to participate in the study in Taleghani hospital, Arak. Blood samples are taken from patients at the beginning of the study(Sampling is done in the clinic)and factors such as blood fat and etc. are measured in the blood(measurement is done in the Arak university of medical sciences laboratory).Then, the herbal medicine will be used in the participants for 12 weeks, and after this period, blood samples will be taken again and the factors will be measured again in order to evaluate the effect of the medicine. Patients will not be aware of the type of drug and the statistician will not be aware of the type of groups.
The purpose of the study and how to do it will be explained to patients and written consent will be obtained from them to participate in the study in Taleghani hospital, Arak. Blood samples are taken from patients at the beginning of the study (Samplingstudy(Sampling is done in the clinic) andclinic)and factors such as blood fat and etc. are measured in the blood (measurementblood(measurement is done in the Arak university of medical sciences laboratory).Then, the herbal medicine will be used in the participants for 12 weeks, and after this period, blood samples will be taken again and the factors will be measured again in order to evaluate the effect of the medicine. Patients will not be aware of the type of drug and the statistician will not be aware of the type of groups.
هدف از مطالعه و نحوه انجام آن به بیماران توضیح داده خواهد شد و رضایت نامه کتبی جهت شرکت در مطالعه از آنها اخذ خواهد شد. در ابتدای مطالعه از بیماران نمونه خون گرفته می شود (نمونه گیری در کلینیک صورت می گیرد) و فاکتورهایی نظیر چربی خون و غیره اندازه گیری می شوند (اندازی گیری فاکتورها در آزمایشگاه دانشگاه صورت می گیرد). سپس داروی گیاهی در افراد شرکت کننده در مطالعه به مدت 12هفته مورد استفاده قرار گرفته و پس از این مدت نیز مجددا خونگیری و اندازه گیری فاکتورها به منظور ارزیابی میزان تاثیر دارو انجام خواهد شد. بیماران از نوع داروی مصرفی و متخصص آمار از گروه بندی انجام شده اطلاع نخواهند داشت.
هدف از مطالعه و نحوه انجام آن به بیماران توضیح داده خواهد شد و رضایت نامه کتبی جهت شرکت در مطالعه، در بیمارستان طالقانی اراک از آنها اخذ خواهد شد. در ابتدای مطالعه از بیماران نمونه خون گرفته می شود (نمونه گیری در کلینیک صورت می گیرد) و فاکتورهایی نظیر چربی خون و غیره اندازه گیری می شوند (اندازه گیری فاکتورها در آزمایشگاه دانشگاه علوم پزشکی اراک صورت می گیرد). سپس داروی گیاهی در افراد شرکت کننده در مطالعه به مدت 12هفته مورد استفاده قرار گرفته و پس از این مدت نیز مجددا خونگیری و اندازه گیری فاکتورها به منظور ارزیابی میزان تاثیر دارو انجام خواهد شد. بیماران از نوع داروی مصرفی و متخصص آمار از گروه بندی انجام شده اطلاع نخواهند داشت.
هدف از مطالعه و نحوه انجام آن به بیماران توضیح داده خواهد شد و رضایت نامه کتبی جهت شرکت در مطالعه، در بیمارستان طالقانی اراک از آنها اخذ خواهد شد. در ابتدای مطالعه از بیماران نمونه خون گرفته می شود (نمونه گیری در کلینیک صورت می گیرد) و فاکتورهایی نظیر چربی خون و غیره اندازه گیری می شوند (اندازیاندازه گیری فاکتورها در آزمایشگاه دانشگاه علوم پزشکی اراک صورت می گیرد). سپس داروی گیاهی در افراد شرکت کننده در مطالعه به مدت 12هفته مورد استفاده قرار گرفته و پس از این مدت نیز مجددا خونگیری و اندازه گیری فاکتورها به منظور ارزیابی میزان تاثیر دارو انجام خواهد شد. بیماران از نوع داروی مصرفی و متخصص آمار از گروه بندی انجام شده اطلاع نخواهند داشت.
The inclusion criteria for the study are: women in the age range of 18-45 years; whose PCOS has been confirmed by a specialist doctor; Only patients who do not intend to become pregnant are allowed to enter our study because the profile of therapeutic drugs of people who intend to become pregnant is different from those who do not intend to become pregnant. The exclusion criteria are: consumption anticoagulant drugs and antioxidant and anti-inflammatory supplements 3 months before the study; suffering from diabetes; thyroid disorders; and hyperprolactinemia.
women in the age range of 18-45 years;whose PCOS has been confirmed by a specialist doctor;Only patients who do not intend to become pregnant are allowed to enter our study because the profile of therapeutic drugs of people who intend to become pregnant is different from those who do not intend to become pregnant.The exclusion criteria are:consumption anticoagulant drugs and antioxidant and anti-inflammatory supplements 3 months before the study; suffering from diabetes;thyroid disorders;and hyperprolactinemia.
The inclusion criteria for the study are: women in the age range of 18-45 years;whose PCOS has been confirmed by a specialist doctor;Only patients who do not intend to become pregnant are allowed to enter our study because the profile of therapeutic drugs of people who intend to become pregnant is different from those who do not intend to become pregnant. Thepregnant.The exclusion criteria are:consumption anticoagulant drugs and antioxidant and anti-inflammatory supplements 3 months before the study; suffering from diabetes;thyroid disorders;and hyperprolactinemia.
معیار های ورود به مطالعه عبارت اند از: زنان در محدوده ی سنی 45-18 سال که ابتلای آنها به PCOS توسط پزشک متخصص تایید شده است؛ فقط بیمارانی اجازه ی ورود به مطالعه ی ما را دارند که قصد بارداری نداشته باشند زیرا پروفایل داروهای درمانی افرادی که قصد بارداری دارند با افرادی که قصد بارداری ندارند متفاوت است.
معیار های عدم ورود عبارت اند از: مصرف داروهای ضد انعقادی و مکمل های آنتی اکسیدانی و ضد التهابی به فاصله‌ی 3 ماه قبل از مطالعه؛ ابتلای فرد به دیابت؛ اختلالات تیروئید و هایپرپرولاکتینمی.
زنان در محدوده ی سنی 45-18 سال که ابتلای آنها به PCOS توسط پزشک متخصص تایید شده است؛ فقط بیمارانی اجازه ی ورود به مطالعه ی ما را دارند که قصد بارداری نداشته باشند زیرا پروفایل داروهای درمانی افرادی که قصد بارداری دارند با افرادی که قصد بارداری ندارند متفاوت است.
معیار های عدم ورود عبارت اند از: مصرف داروهای ضد انعقادی و مکمل های آنتی اکسیدانی و ضد التهابی به فاصله‌ی 3 ماه قبل از مطالعه؛ ابتلای فرد به دیابت؛ اختلالات تیروئید و هایپرپرولاکتینمی.
معیار های ورود به مطالعه عبارت اند از: زنان در محدوده ی سنی 45-18 سال که ابتلای آنها به PCOS توسط پزشک متخصص تایید شده است؛ فقط بیمارانی اجازه ی ورود به مطالعه ی ما را دارند که قصد بارداری نداشته باشند زیرا پروفایل داروهای درمانی افرادی که قصد بارداری دارند با افرادی که قصد بارداری ندارند متفاوت است. معیار های عدم ورود عبارت اند از: مصرف داروهای ضد انعقادی و مکمل های آنتی اکسیدانی و ضد التهابی به فاصله‌ی 3 ماه قبل از مطالعه؛ ابتلای فرد به دیابت؛ اختلالات تیروئید و هایپرپرولاکتینمی.
Recipient group of Arctium Lappa root (One 460 mg capsule per day) and recipient group contains starch with the same dose.
Recipient group of Arctium Lappa root(One 460 mg capsule per day)and recipient group contains starch with the same dose.
Recipient group of Arctium Lappa root (Oneroot(One 460 mg capsule per day) andday)and recipient group contains starch with the same dose.
General information
empty
60
60
empty
2023-04-04, 1402/01/15
2023-04-04 00:00:00
empty
2024-01-20, 1402/10/30
2024-01-20 00:00:00
empty
Due to the impossibility of accurately counting the number of ovarian follicles as a primary outcome variable, and with the approval of the research council of the relevant center, this outcome was removed from the list of relevant outcomes.
Due to the impossibility of accurately counting the number of ovarian follicles as a primary outcome variable, and with the approval of the research council of the relevant center, this outcome was removed from the list of relevant outcomes.
empty
با توجه به عدم امکان شمارش دقیق تعداد فولیکول های تخمدان به عنوان متغیر پیامد اولیه، و با تایید شورای پژوهشی مرکز مربوطه، این پیامد از لیست پیامد های مربوطه حذف شد.
با توجه به عدم امکان شمارش دقیق تعداد فولیکول های تخمدان به عنوان متغیر پیامد اولیه، و با تایید شورای پژوهشی مرکز مربوطه، این پیامد از لیست پیامد های مربوطه حذف شد.
The effect of Arctium Lappa root powder in women with polycystic ovary syndrome
Investigation the effects of Arctium Lappa root powder in women with polycystic ovary syndrome
The effectInvestigation the effects of Arctium Lappa root powder in women with polycystic ovary syndrome
Effects of Arctium Lappa root powder on some markers of oxidative stress and inflammation in women with polycystic ovary syndrome: a randomized double blind clinical trial study
Investigation the effects of Arctium Lappa root powder on some markers of oxidative stress and inflammation in women with polycystic ovary syndrome: a randomized double blind clinical trial study
EffectsInvestigation the effects of Arctium Lappa root powder on some markers of oxidative stress and inflammation in women with polycystic ovary syndrome: a randomized double blind clinical trial study
از روش تخصیص تصادفی استفاده می‌شود و بيماران با روش تخصیص تصادفی بلوكي با بلوك هاي چهار تايي در گروه مداخله یا كنترل قرار مي‌گيرند. با اختصاص حرف A به گروه مداخله وحرف B به گروه كنترل، شش حالت AABB ،BBAA ،BABA ،ABBA ،BAAB و ABAB در برگه هاي جداگانه نوشته شده و در ظرفي ریخته مي‌شود و هربار يكي از برگه ها از ظرف خارج می‌شود و تركيب نوشته شده در روي آن يادداشت مي شود و مجددا آن برگه به داخل ظرف انداخته مي‌شود. از آنجایی که حجم نمونه در اين مطالعه 60 نفر است اين عمل 15 بار تكرار مي‌شود و هر بار تركيب نوشته شده بر روي هر برگه در دنباله ترتيب نوشته شده برگه قبلي يادداشت مي شود. سپس به هر يك از حروف يك عدد از يك تا شصت به ترتيب حروف يادداشت شده پشت سر هم اختصاص داده مي‌شود و هر يک از حروف داخل يك پاكت گذاشته شده و روي پاكت عدد آن حرف نوشته مي‌شود. هر بار كه بيماري انتخاب مي شود يكي از پاكت ها به ترتيب عدد نوشته شده روي پاكت باز شده و مشخص مي‌شود كه بيمار بايد در گروه مداخله و يا كنترل قرار بگيرد.
از روش تخصیص تصادفی استفاده می‌شود و بيماران با روش تخصیص تصادفی بلوكی با بلوک های چهار تايی در گروه مداخله یا كنترل قرار می گيرند. با اختصاص حرف A به گروه مداخله وحرف B به گروه كنترل، شش حالت AABB ،BBAA ،BABA ،ABBA ،BAAB و ABAB در برگه های جداگانه نوشته شده و در ظرفی ریخته می شود و هربار يكی از برگه ها از ظرف خارج می‌شود و تركيب نوشته شده در روی آن يادداشت می شود و مجددا آن برگه به داخل ظرف انداخته می شود. از آنجایی که حجم نمونه در اين مطالعه 60 نفر است اين عمل 15 بار تكرار می شود و هر بار تركيب نوشته شده بر روی هر برگه در دنباله ترتيب نوشته شده برگه قبلی يادداشت می شود. سپس به هر يك از حروف يك عدد از يك تا شصت به ترتيب حروف يادداشت شده پشت سر هم اختصاص داده می شود و هر يک از حروف داخل يک پاكت گذاشته شده و روی پاكت عدد آن حرف نوشته می شود. هر بار كه بيماری انتخاب می شود يكی از پاكت ها به ترتيب عدد نوشته شده روی پاكت باز شده و مشخص می شود كه بيمار بايد در گروه مداخله و يا كنترل قرار بگيرد.
از روش تخصیص تصادفی استفاده می‌شود و بيماران با روش تخصیص تصادفی بلوكيبلوكی با بلوك هايبلوک های چهار تاييتايی در گروه مداخله یا كنترل قرار ميمی گيرند. با اختصاص حرف A به گروه مداخله وحرف B به گروه كنترل، شش حالت AABB ،BBAA ،BABA ،ABBA ،BAAB و ABAB در برگه هايهای جداگانه نوشته شده و در ظرفيظرفی ریخته ميمی شود و هربار يكييكی از برگه ها از ظرف خارج می‌شود و تركيب نوشته شده در رويروی آن يادداشت ميمی شود و مجددا آن برگه به داخل ظرف انداخته ميمی شود. از آنجایی که حجم نمونه در اين مطالعه 60 نفر است اين عمل 15 بار تكرار ميمی شود و هر بار تركيب نوشته شده بر رويروی هر برگه در دنباله ترتيب نوشته شده برگه قبليقبلی يادداشت ميمی شود. سپس به هر يك از حروف يك عدد از يك تا شصت به ترتيب حروف يادداشت شده پشت سر هم اختصاص داده ميمی شود و هر يک از حروف داخل يكيک پاكت گذاشته شده و رويروی پاكت عدد آن حرف نوشته ميمی شود. هر بار كه بيماريبيماری انتخاب ميمی شود يكييكی از پاكت ها به ترتيب عدد نوشته شده رويروی پاكت باز شده و مشخص ميمی شود كه بيمار بايد در گروه مداخله و يا كنترل قرار بگيرد.
Primary outcomes
#1
پروتئین واکنشی C با حساست بالا
پروتئین واکنشی C با حساسیت بالا
پروتئین واکنشی C با حساستحساسیت بالا
#2
The number of ovarian follicles
Ovary volume
The number of ovarian folliclesOvary volume
تعداد فولیکول های تخمدان
حجم تخمدان
تعداد فولیکول هایحجم تخمدان
#3
Ovary volume
The rate of hirsutism
Ovary volumeThe rate of hirsutism
حجم تخمدان
میزان هیرسوتیسم
حجم تخمدانمیزان هیرسوتیسم
Ultrasonography
Ferriman-Gallwey scoring scale
UltrasonographyFerriman-Gallwey scoring scale
سونوگرافی
مقیاس نمره دهی فریمن-گالوی
سونوگرافیمقیاس نمره دهی فریمن-گالوی
#4
The rate of hirsutism
Number of periods
The rateNumber of hirsutismperiods
میزان هیرسوتیسم
تعداد قاعدگی
میزان هیرسوتیسمتعداد قاعدگی
Ferriman-Gallwey scoring scale
To ask the patient
Ferriman-Gallwey scoring scaleTo ask the patient
مقیاس نمره دهی فریمن-گالوی
پرسش از بیمار
مقیاس نمره دهی فریمن-گالویپرسش از بیمار
#5
Number of periods
empty
Number of periods
تعداد قاعدگی
empty
تعداد قاعدگی
Before and after 12 weeks of intervention
empty
Before and after 12 weeks of intervention
قبل از مداخله و 12 هفته بعد از مداخله
empty
قبل از مداخله و 12 هفته بعد از مداخله
To ask the patient
empty
To ask the patient
پرسش از بیمار
empty
پرسش از بیمار
Protocol summary
Study aim
Effects of Arctium Lappa root on serum levels of some biochemical variables in women with polycystic ovary syndrome
Design
In this randomized, double-blind, phase 2 study, a total number of 60 people with polycystic ovary syndrome will be selected. They will be divided into two groups of Arctium Lappa root and placebo by block randomization method. They will be matched in age and BMI.
Settings and conduct
The purpose of the study and how to do it will be explained to patients and written consent will be obtained from them to participate in the study in Taleghani hospital, Arak. Blood samples are taken from patients at the beginning of the study(Sampling is done in the clinic)and factors such as blood fat and etc. are measured in the blood(measurement is done in the Arak university of medical sciences laboratory).Then, the herbal medicine will be used in the participants for 12 weeks, and after this period, blood samples will be taken again and the factors will be measured again in order to evaluate the effect of the medicine. Patients will not be aware of the type of drug and the statistician will not be aware of the type of groups.
Participants/Inclusion and exclusion criteria
women in the age range of 18-45 years;whose PCOS has been confirmed by a specialist doctor;Only patients who do not intend to become pregnant are allowed to enter our study because the profile of therapeutic drugs of people who intend to become pregnant is different from those who do not intend to become pregnant.The exclusion criteria are:consumption anticoagulant drugs and antioxidant and anti-inflammatory supplements 3 months before the study; suffering from diabetes;thyroid disorders;and hyperprolactinemia.
Intervention groups
Recipient group of Arctium Lappa root(One 460 mg capsule per day)and recipient group contains starch with the same dose.
Main outcome variables
Markers of oxidative stress and inflammation
General information
Reason for update
Due to the impossibility of accurately counting the number of ovarian follicles as a primary outcome variable, and with the approval of the research council of the relevant center, this outcome was removed from the list of relevant outcomes.
Acronym
IRCT registration information
IRCT registration number:IRCT20230222057492N1
Registration date:2023-03-29, 1402/01/09
Registration timing:prospective
Last update:2024-06-08, 1403/03/19
Update count:4
Registration date
2023-03-29, 1402/01/09
Registrant information
Name
Hanieh Taheri
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 86 3383 8278
Email address
hanieh.taheri@arakmu.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-04-04, 1402/01/15
Expected recruitment end date
2024-04-03, 1403/01/15
Actual recruitment start date
2023-04-04, 1402/01/15
Actual recruitment end date
2024-01-20, 1402/10/30
Trial completion date
empty
Scientific title
Investigation the effects of Arctium Lappa root powder on some markers of oxidative stress and inflammation in women with polycystic ovary syndrome: a randomized double blind clinical trial study
Public title
Investigation the effects of Arctium Lappa root powder in women with polycystic ovary syndrome
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Women in the age range of 18-45 years
Confirmation of PCOS by a specialist doctor
Patient satisfaction to enter the study
Patients who do not intend to become pregnant because the profile of therapeutic drugs for people who intend to become pregnant is different from those who do not intend to become pregnant
Exclusion criteria:
Smoking
consumption of anticoagulant drugs and antioxidant and anti-inflammatory supplements for 3 months before the study.
Pregnancy
Breastfeeding
Diabetes
Thyroid disorders
Hyperprolactinemia
Age
From 18 years old to 45 years old
Gender
Female
Phase
2-3
Groups that have been masked
Participant
Care provider
Data analyser
Sample size
Target sample size:
60
Actual sample size reached:
60
Randomization (investigator's opinion)
Randomized
Randomization description
The random allocation method will be used and the patients are placed in the intervention or control group using the block random allocation method with blocks of four. By assigning the letter A to the intervention group and the letter B to the control group, six states AABB, BBAA, BABA, ABBA, BAAB, and ABAB are written on separate sheets and are thrown into a container, and each time one of the sheets is taken out and it's written composition is noted and the sheet is thrown into the container again. Since the sample size in this study is 60, this procedure is repeated 15 times and each time the combination written on each sheet is noted in the sequence of the previous sheet. Then, a number from one to sixty is assigned to each of the letters in the order of the letters noted one after the other, and each of the letters are placed in an envelope and the specific number of each letter is written on the envelope. Every time which a subject is selected, one of the envelopes is opened. According to the number written on the envelope, the patient is introduced into the intervention or control group.
Blinding (investigator's opinion)
Double blinded
Blinding description
Participants, healthcare providers, and outcome assessors are blinded. The drug and placebo are packaged in similar packages. The treatment group and placebo group will not be aware of the type of intervention they receive. The statistician will not be informed about the grouping done.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Arak University of Medical Sciences
Street address
Arak University of Medical Sciences, Basij Square, Sardasht, Arak
City
Arak
Province
Markazi
Postal code
3848176941
Approval date
2023-02-12, 1401/11/23
Ethics committee reference number
IR.ARAKMU.REC.1401.334
Health conditions studied
1
Description of health condition studied
Polycystic ovary syndrome
ICD-10 code
E28.2
ICD-10 code description
Polycystic ovarian syndrome
Primary outcomes
1
Description
Superoxide dismutase
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
2
Description
Catalase
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
3
Description
Glutathione peroxidase
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
4
Description
Reduced glutathione
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
5
Description
Oxidized glutathione
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
6
Description
The ratio of reduced glutathione to oxidized glutathione
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
7
Description
Total antioxidant capacity
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
8
Description
Total oxidant status
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
9
Description
Oxidative stress index
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
10
Description
Malondialdehyde
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
11
Description
Ratio of malondialdehyde to total antioxidant capacity
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
12
Description
Total antioxidant gap
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
13
Description
Total Thiol
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Colorimetric
14
Description
High-sensitivity C-reactive protein
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Immunoturbidimetry
15
Description
The ratio of high-sensitivity C-reactive protein to albumin
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
16
Description
The ratio of blood urea nitrogen to albumin
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
17
Description
Albumin bilirubin score
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
18
Description
Triglyceride-Glucose index
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
19
Description
Ovary volume
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Ultrasonography
20
Description
The rate of hirsutism
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Ferriman-Gallwey scoring scale
21
Description
Number of periods
Timepoint
Before and after 12 weeks of intervention
Method of measurement
To ask the patient
Secondary outcomes
1
Description
Body mass index
Timepoint
Before and after 12 weeks of intervention
Method of measurement
Formula
Intervention groups
1
Description
Intervention group: One capsule Arctium Lappa root powder (460 mg) per day for 12 weeks.
Category
Treatment - Drugs
2
Description
Control group: One capsule placebo starch (460 mg) per day for 12 weeks.
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
Taleghani Hospital
Full name of responsible person
Hanieh Taheri
Street address
Shora Square, Imam Khomeini Street, Arak
City
Arak
Province
Markazi
Postal code
3848176941
Phone
+98 86 3277 4001
Email
haniehtaheri1997@yahoo.com
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Mehdi Salehi
Street address
Arak University of Medical Sciences, Basij Square, Sardasht, Arak
City
Arak
Province
Markazi
Postal code
3848176941
Phone
+98 86 3417 3638
Email
Research@arakmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Arak University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Hanieh Taheri
Position
Master Student
Latest degree
Master
Other areas of specialty/work
Biochemistry
Street address
Department of Biochemistry, School of Medicine, Arak University of Medical Sciences, Basij Square, Sardasht, Arak
City
Arak
Province
Markazi
Postal code
3848176941
Phone
+98 86 3417 3645
Email
haniehtaheri1997@yahoo.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Hanieh Taheri
Position
Master Student
Latest degree
Master
Other areas of specialty/work
Biochemistry
Street address
Department of Biochemistry, School of Medicine, Arak University of Medical Sciences, Basij Square, Sardasht, Arak
City
Arak
Province
Markazi
Postal code
3848176941
Phone
+98 86 3417 3645
Email
haniehtaheri1997@yahoo.com
Person responsible for updating data
Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Hanieh Taheri
Position
Master Student
Latest degree
Master
Other areas of specialty/work
Biochemistry
Street address
Department of Biochemistry, School of Medicine, Arak University of Medical Sciences, Basij Square, Sardasht, Arak
City
Arak
Province
Markazi
Postal code
3848176941
Phone
+98 86 3417 3645
Email
haniehtaheri1997@yahoo.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
Only results of main outcomes
When the data will become available and for how long
Six months after publishing of the results
To whom data/document is available
Only for academic staffs and universities researches
Under which criteria data/document could be used
Only for international and between universities researches
From where data/document is obtainable
Ali Khosrowbeygi a.khosrowbeygi@arakmu.ac.ir
What processes are involved for a request to access data/document
1. Requesting a team work clinical trial via email. 2. Approving the proposal. 3. Registration of the trial.